scholarly journals Addressing type 1 diabetes health inequities in the United States: Approaches from the T1D Exchange QI Collaborative

2021 ◽  
Author(s):  
Osagie Ebekozien ◽  
Ann Mungmode ◽  
Oriyomi Odugbesan ◽  
Shideh Majidi ◽  
Priya Prahalad ◽  
...  
BMC Medicine ◽  
2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Mary A. M. Rogers ◽  
Catherine Kim ◽  
Tanima Banerjee ◽  
Joyce M. Lee

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Michael F Knoll ◽  
Carmela A Knoll ◽  
Rita Bottino ◽  
Massimo Trucco ◽  
Suzanne Bertera ◽  
...  

Clinical islet transplantation was first realized over four decades ago at the University of Minnesota. Autologous islet transplantation is now widely recognized as a treatment to prevent diabetes in patients after pancreas excision and is offered at major transplant centers throughout the United States and the world. Type 1 diabetes represents a much larger demographic in which islet transplantation may benefit patients. Allogeneic islet transplantation can now offer similar outcomes to pancreas transplantation in a subset of patients with labile type 1 diabetes with less risk than whole organ transplantation. It is recognized as a standard of care in nations around the world but not in the United States, despite the important developmental role US scientists and physicians have played. Early reports of islet transplantation focused on insulin independence that proved to diminish over time. However, regardless of insulin status, islet transplantation provides benefits ranging from improved quality of life to reduction in diabetic complications. A National Institutes of Health sponsored multi-center Phase 3 Clinical Trial (CIT-07) demonstrated safety and efficacy, although the Food and Drug Administration chose to consider islets as a biologic that requires licensure, which makes offering the procedure in the clinic very challenging. Until regulations can be brought into communion with international standards, allogeneic islet transplantation in the United States is unlikely to match international levels of success and once promising programs are left to wither on the vine. Food and Drug Administration approval would open the door for third party medical reimbursement and allow many patients the opportunity to enjoy better health and quality of life. Establishment of clinical islet transplantation for type 1 diabetes would lead to optimizations in procedures making it more efficacious and cost effective while offering support for ongoing islet xenotransplantation studies that could bring islet transplantation to even more patients.


2020 ◽  
Vol 26 (3) ◽  
pp. 311-318
Author(s):  
Vijay N. Joish ◽  
Fang Liz Zhou ◽  
Ronald Preblick ◽  
Dee Lin ◽  
Maithili Deshpande ◽  
...  

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 1122-P
Author(s):  
DUSTIN ROWLAND ◽  
NICOLE D.O. LEE ◽  
BERRIN ERGUN-LONGMIRE

2016 ◽  
Vol 122 ◽  
pp. 28-37 ◽  
Author(s):  
Ruth S. Weinstock ◽  
Ingrid Schütz-Fuhrmann ◽  
Crystal G. Connor ◽  
Julia M. Hermann ◽  
David M. Maahs ◽  
...  

2021 ◽  
pp. 193229682110064
Author(s):  
Ananta Addala ◽  
Sarah Hanes ◽  
Diana Naranjo ◽  
David M. Maahs ◽  
Korey K. Hood

Background: Diabetes technology use is associated with favorable type 1 diabetes (T1D) outcomes. American youth with public insurance, a proxy for low socioeconomic status, use less diabetes technology than those with private insurance. We aimed to evaluate the role of insurance-mediated provider implicit bias, defined as the systematic discrimination of youth with public insurance, on diabetes technology recommendations for youth with T1D in the United States. Methods: Multi-disciplinary pediatric diabetes providers completed a bias assessment comprised of a clinical vignette and ranking exercises ( n = 39). Provider bias was defined as providers: (1) recommending more technology for those on private insurance versus public insurance or (2) ranking insurance in the top 2 of 7 reasons to offer technology. Bias and provider characteristics were analyzed with descriptive statistics, group comparisons, and multivariate logistic regression. Results: The majority of providers [44.1 ± 10.0 years old, 83% female, 79% non-Hispanic white, 49% physician, 12.2 ± 10.0 practice-years] demonstrated bias ( n = 33/39, 84.6%). Compared to the group without bias, the group with bias had practiced longer (13.4±10.4 years vs 5.7 ± 3.6 years, P = .003) but otherwise had similar characteristics including age (44.4 ± 10.2 vs 42.6 ± 10.1, p = 0.701). In the logistic regression, practice-years remained significant (OR = 1.47, 95% CI [1.02,2.13]; P = .007) when age, sex, race/ethnicity, provider role, percent public insurance served, and workplace location were included. Conclusions: Provider bias to recommend technology based on insurance was common in our cohort and increased with years in practice. There are likely many reasons for this finding, including healthcare system drivers, yet as gatekeepers to diabetes technology, providers may be contributing to inequities in pediatric T1D in the United States.


Sign in / Sign up

Export Citation Format

Share Document